NCT02452372 - A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2015

Primary Completion Date

September 6, 2017

Study Completion Date

September 6, 2017

Conditions

Acute Intermittent Porphyria

Interventions

DRUG

givosiran (ALN-AS1)

Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

calculated volume to match active comparator

Trial Locations (6)

Clinical Trial Site, Birmingham

Clinical Trial Site, San Francisco

Clinical Trial Site, New York

Clinical Trial Site, Galveston

Clinical Trial Site, Stockholm

Clinical Trial Site, London